1,721,161 research outputs found

    [Girolamo Legnani (c.1805), funerary sculpture]

    No full text
    From Berresford: Girolamo Legnani (c.1805), Giuseppe Tadolini and Petronio Ricci, Cimitero della Certosa, Bologna.Painted tomb.Title from Berresford

    Diagnosis of deep vein thrombosis.

    No full text
    Deep vein thrombosis (DVT) requires a prompt and accurate diagnosis to avoid the potentially fatal consequences of a delay in adequate treatment. The diagnostic strategy of suspected venous thromboembolism is an example of the application of Bayes' theorem. As a result, the available diagnostic tools, both noninvasive (such as ultrasonography, D-dimer, and computed tomography) and invasive (such as venography), are usually integrated in diagnostic strategies that require the evaluation of the a priori clinical probability of disease (pretest probability). These strategies also vary according to the patient characteristics that allow the definition of five different categories: symptomatic outpatients, symptomatic inpatients, high-risk asymptomatic subjects, patients with suspected recurrence, and pregnant women. Some areas are still a matter of debate, such as the clinical relevance of isolated distal DVT and the diagnosis of suspected ipsilateral recurrence

    Role of family history in identifying women with thrombophilia and higher risk of venous thromboembolism during oral contraception

    No full text
    Background: Unrecognized thrombophilic defects increase the risk of venous thromboembolism (VTE) in women during oral contraception (OC). We evaluated the sensitivity and specificity of a family history of VTE to identify thrombophilia in women before OC and after venous thrombotic complications during OC. Methods: Thrombophilia screening was performed after obtaining a family history by means of a standardized questionnaire in (1) thrombosis-free women before OC and (2) women after an episode of VTE during OC. Results: We evaluated 479 thrombosis-free women before OC (age range, 15-49 years); family history was positive in 49 (10.2%). Thrombophilic defects were identified in 36 participants (7.5%; 95% confidence interval [CI], 5%-10%), 3 of whom had a positive family history (8.3%). The sensitivity and positive predictive value of family history of thrombophilic defects were 8.3% (95% CI, 2%-22%) and 6.1% (95% CI, 1%-17%), respectively. We also evaluated 189 women after VTE complications during OC (age range, 15-49 years); family history was positive in 48 (25.4%; 95% CI, 19%-32%), 22 of whom had a thrombophilic defect (45.8%; 95% CI, 31%-61%). Thrombophilic defects were identified in 81 women (42.8%; 95% CI, 36%-50%). The sensitivity and positive predictive value of family history of thrombophilic defects were 27.2% (95% CI, 18%-38%) and 45.8% (95% CI 31%-61%), respectively. Conclusion: Family history of VTE has low sensitivity and positive predictive value for identifying women with thrombophilia who are more susceptible to VTE complications during OC

    Value of family history in identifying women at risk of venous thromboembolism during oral contraception: Observational study

    No full text
    Common inherited thrombophilic defects such as factor V Leiden and G20120A mutation of the prothrombin gene inter act synergistically with oral contraceptives to increase the risk of venous thromboembolism.(1 2) The best approach to identify women at higher risk of venous thromboembolism before taking oral contraceptives is controversial. Universal screening is not cost effective because 8000 women need to be screened for factor V Leiden to detect 400 mutations and prevent one episode of venous thromboembolism.(1) Many authors recommend selective screening in women with a personal or family history of venous thromboembolism.(1) However; the effectiveness of this approach has not been proved, The aim of our study was to evaluate the sensitivity and positive predictive value of a family history of venous thromboembolism for identifying common thrombophilic defects in women without thrombosis before taking oral contraceptives
    corecore